All In Biotech

Investigational drug · Phase 3

Pemetrexed and Cisplatin

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced or Metastatic NSCLC.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

663

Any phase or sponsor naming "Pemetrexed and Cisplatin"

First trial start

2026

Oct 23, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Pemetrexed and Cisplatin", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced or Metastatic NSCLC

Approved drugs for the same conditions: Non-small cell lung cancer

Largest trials

Live from ClinicalTrials.gov: studies naming "Pemetrexed and Cisplatin" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 213 on PubMed

Also in development for Advanced or Metastatic NSCLC

  • CeralasertibAZD6738Phase 35 trials

    AstraZeneca · Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer

  • HS-10504Phase 31 trial

    Jiangsu Hansoh Pharmaceutical Co., Ltd. · Advanced or Metastatic NSCLC

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.